

## Preliminary Program

All times CDT

### Friday, October 2, 2020

#### 08:00 – 08:25 Welcome and Opening Keynote

- Chair's Welcome
- Personalizing Lung Cancer Treatment – Pasi Janne, USA
- Live Q&A

#### 08:25 – 09:35 Understanding the Basics for Liquid Biopsy (ctDNA)

Chair: Lynette Sholl, USA

- Preanalytics in ctDNA Handling: A Crucial Point – Umberto Malapelle, Italy
- Technologies Update from Single to Multiple Determinations – Ignacio Wistuba, USA
- Advantages and Disadvantages to In-house vs Outsourcing Analyses with Liquid Biopsy – David R. Gandara, USA & Maria Arcila, USA
- Live Q&A with all Presenters Moderated by Lynette Sholl, USA

#### 09:35 – 09:50 Break

#### 09:50 – 11:20 Clinical Application of Liquid Biopsy (ctDNA)

Chair: Natasha Leighl, Canada


- Integrating Liquid Biopsy into Clinical Practice: Which Patients with NSCLC? – Natasha Leighl, Canada
- Presentation of IALSC Consensus Statement Results – Christian Rolfo, USA
- Clinical Cases in Molecular Tumor Board Debate – Natasha Leighl, Canada; Lecia Sequist, USA; Tony Mok, Hong Kong
- Q&A moderated by Natasha Leighl, Canada
- Cross Fire Session: Liquid versus Tissue Biopsy... or Complementary – Marina Garassino, Italy & Maria Arcila, USA
- Quantitation of Variant Allele Frequency and Variants in the Decision-Making Process: Molecular Biology Perspective and Pathology Perspective – Phil Mack, USA & Lynette Sholl, USA
- Live Q&A with all Presenters Moderated by Natasha Leighl, Canada

#### 11:20 – 11:35 Break

#### 11:35 – 12:15 Prime Time for Blood First

Chair: Maria Arcila, USA

- No, It Is Not Prime Time – Fred R. Hirsch, USA
- Yes, It Is Prime Time – Rafal Dziadziuszko, Poland
- Live Q&A with all Presenters Moderated by Maria Arcila, USA



## Preliminary Program

All times CDT

### 12:15 – 13:40 Liquid Biopsy and Checkpoint Immunotherapy (CPI)

**Chairs:** Benjamin Besse, France & Shirish Gadgil, USA

- Tumor Mutational Burden (TMB): Moving from Tumor Tissue to Blood – Phil Mack, USA
- TMB as a Potential Predictive Biomarker for CPI – Solange Peters, Switzerland
- Analytical and Clinical Validation of a Blood TMB Assay – David R. Gandara, USA
- Other Potential Predictive Biomarkers in ctDNA for CPI – Maximilian Diehn, USA
- Live Q&A with all Presenters
- Closing Remarks of the Day – Giorgio Scagliotti, Italy

## Saturday, October 3, 2020

### 08:00 – 08:55 What Are the Real Challenges for a Worldwide Application?

**Chairs:** Kazuto Nishio, Japan & Harpreet Singh, USA & Christian Rolfo, USA

- Panel Discussion: What Are the Real Challenges for a Worldwide Application?
  - o Laureen Leiman, USA
  - o Nikki Martin, USA
  - o Michelle Turner, USA
  - o Harpreet Singh, USA
  - o Chandra Belani, USA
- Liquid Biopsy Regulations from FDA Perspective – Harpreet Singh, USA
- Live Q&A with all Presenters Moderated by Christian Rolfo, USA

### 08:55 – 09:35 Understanding Other Members of the Liquid Biopsy Family

**Chair:** Harpreet Singh, USA


- Liquid Biopsy and Clonal Evolution of Lung Cancer
- Cancer Interception: A New Opportunity for Liquid Biopsy – Maximilian Diehn, USA
- Live Q&A with all Presenters Moderated by Harpreet Singh, USA

### 09:35 – 09:50 Break

### 09:50 – 11:40 Increasing Roles for Liquid Biopsy: Moving from Research to Clinical Application

**Chairs:** Chandra Belani, USA & Charu Aggarwal, USA

- Detection of Early Stage Disease: Complementary or Replacement for CT Screening – Nir Peled, Israel
- Early Detection of Recurrence after Surgery: TRACERx, Minimal Residual Disease and Adjuvant Trials – Chris Abbosh, UK
- Liquid Biopsy for Detection of Minimal Residual Disease – Tetsuya Mitsudomi, Japan
- Q&A moderated by Charu Aggarwal, USA
- Liquid Biopsy for Tumor Monitoring – Natasha Leighl, Canada



## Preliminary Program

All times CDT

- Liquid Biopsy for Determination of Mechanisms of Resistance – Charu Aggarwal, USA
- ctRNA: Exploring Other Opportunities in Liquid Biopsy – Luis Raez, USA
- Live Q&A with all Presenters Moderated by Chandra Belani, USA

**11:40 – 12:40 Break**

**12:40 – 13:20 Liquid Biopsy in Clinical Trials**

**Chair:** Christian Rolfo, USA

- Integrating Liquid Biopsy in Lung Cancer Clinical Trial Design – Benjamin Besse, France
- Update of the Ongoing Trials in Liquid Biopsy – Rafal Dziadziuszko, Poland
- Live Q&A with all Presenters Moderated by Christian Rolfo, USA


**13:20 – 14:00 Molecular Tumor Board Discussion**

**Chair:** Shirish Gadgeel, USA

- Panel Discussion:
  - o Lynette Sholl, USA
  - o Umberto Malapelle, Italy
  - o Marina Garassino, Italy
  - o Charu Aggarwal, USA
- Live Q&A with all Presenters Moderated by Shirish Gadgeel, USA

**14:00 – 14:15 Closing Session**

- Closing Remarks:
  - o Christina Rolfo, USA
  - o Maria Arcila, USA
  - o David R. Gandara, USA




## Preliminary Program

All times CDT

### POSTERS


- Potential of Plasma Circulating Tumor DNA as a Monitoring Tool in Patients with Advanced EGFR-mutated NSCLC - Vichitra Behel, India
- Discovery of Targetable Genetic Alterations in Plasma of Non-small Cell Lung Cancer Patients with Brain Metastases Using a MassARRAY-based Circulating Tumor DNA Assay - Yassine Belloum, Germany
- Treatment Induced Tumor Lysis to Enhance Sensitivity of ctDNA Analysis and Its Prognostic Value: A First-in-human Pilot Study - Daniel Breadner, Canada
- Circulating Tumor Cells and Tissue AXL as the New Prognostic Biomarkers in Resected Non-small Cell Lung Cancer Patients. - Diego De Miguel Perez, USA
- Extracellular Vesicle miRNAs and Autophagy-activated CTCs Are Predictive and Prognostic Biomarkers in Advanced Non-small Cell Lung Cancer Patients. - Diego De Miguel Perez, USA
- Identification of New Biomarkers in Non-Small Cell Lung Cancer (NSCLC) by Analyzing Exosomes Cargo - Elena Duréndez-Sáez, Spain
- Longitudinal Disease Monitoring of Circulating Tumor DNA in EGFR T790M Mutation-positive Non-small-cell Lung Cancer Patients Receiving Treatment with Osimertinib (WJOG8815L) - Asuka Okada, Japan
- Pilot Study of a Novel Liquid Biopsy Test to Discriminate Benign vs Malignant Processes in Subjects with Indeterminate Pulmonary Nodules - Paul Pagano, USA
- Clinical Utility of Circulating Genetically Abnormal Cells in Differential Diagnosis of Benign from Malignant Pulmonary Nodules Sized Between 5-10mm - Jiayuan Sun, China
- Mutational Landscape and Tumor Mutation Burden of Indian NSCLC Patients - Dadasheb Akolkar, USA
- Detection of Resistant T790M Mutation of EGFR from Pleural Effusion and Other Body Fluids in Lung Adenocarcinoma Patients - Chougule Anuradha, India
- Molecular Characterization of Lung Cancer Brain and Leptomeningeal Metastases via Clinical Next Generation Sequencing of Cell-Free DNA From Cerebrospinal Fluid - Tejus A Bale, USA
- Shifting Paradigms in the Detection of Primary EGFR Mutations - Ullas Batra, India
- Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal Involvement - David Berz, USA
- Analysis of Plasma-derived Extracellular Vesicle (EV) Cargo Using the nCounter Nanostring Platform - Jillian Bracht, Spain
- A Pilot of Diagnostic Circulating Tumour (ct) DNA Next Generation Sequencing (NGS) Assessment in Patients with Suspected Advanced Lung Cancer During the COVID-19 Pandemic - Wanyuan Cui, UK
- Clinical Utility of ctDNA Next Generation Sequencing (NGS) for Target Identification in Diagnostic and Acquired Resistance Settings in Metastatic NSCLC – A Single Centre Experience - Wanda Cui, UK
- Characterization of Peripheral T-Cell Receptor  $\beta$  Chain Repertoire in Advanced Non-small Cell Lung Cancer Patients Treated with Pembrolizumab - Ning Dong, Spain



## Preliminary Program

### All times CDT

- Predictive and Prognostic Role of Soluble Biomarkers in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD1/PDL1 Immunotherapy - Sandra Gallach, Spain
- The Prognostic Impact of Blood Tumor Mutational Burden (bTMB) in the First-line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis of Randomized Trials - Valerio Gristina, Italy
- Molecular Features of Gene Alteration Profiles in Circulating Cell-free DNA of Advanced Non-small Cell Lung Cancer Patients - Hideharu Kimura, Japan
- The VALUE of Routine Liquid Biopsy for NSCLC Patients in a Public Healthcare System - Natasha Leighl, Canada
- Non-invasive Diagnostic Triaging of Suspected Lung Cancers Based on Immunocytochemistry Profiling of Circulating Tumor Cells - Sewanti Limaye, India
- Circulating Free DNA Expression in Lung Cancer Surgical Patients - Joana Espiga de Macedo, Portugal
- The role of liquid biopsy in Non-Small Cell Lung Cancer basal setting patients: focus on KRAS mutations. - Umberto Malapelle, Italy
- The Role of Liquid Biopsy in Non-Small Cell Lung Cancer Basal Setting Patients: Focus on EGFR Mutations. - Umberto Malapelle, Italy
- The Role of Liquid Biopsy in Lung Cancer: Focus on Prevention. - Umberto Malapelle, Italy
- Lung Cancer Testing Using Sputum: A Non-Invasive Liquid Biopsy - Michael Meyer, USA
- NGS-based Liquid Biopsy as a Non-invasive Tool to Identify Targetable Alterations in Non-Small-Cell Lung Cancer (NSCLC) Patients - Andrea Moreno, Spain
- Use of an Artificial Intelligence-derived Algorithm for Accurate FISH Probe Detection in a Liquid Biopsy Test for Lung Cancer - Paul Pagano, USA
- Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer - Cheol-kyu Park, Korea
- Real-World Data: Importance of Monitoring Blood-Based KRAS Mutations and Immune Status in Patients with advanced NSCLC - Edgardo Santos, USA
- The Turnaround Time Impact of Liquid Biopsy in Comparison with Tissue Biopsy in Advance NSCLC - Or Sehayek, Israel
- Improved Lung Cancer Prediction by Combining Lung EpiCheck and Clinical Risk Factors - Aharon Shuali, Israel
- Changes in cfDNA Levels in Squamous Non-small Cell Lung Cancer Following Chemotherapy: Correlation with Symptom Scores and Radiological Responses - Navneet Singh, India
- Gene Mutation Profiles in Liquid Biopsies Upon Development of Resistance to Afatinib - Nanao Terada, USA
- Clinical Utility of Personalised Somatic Genomic Rearrangement Biomarkers after Surgical Resection of Non-small Cell Lung Cancer - Boris Wong, Australia
- Ultra-rapid Detection of Circulating EGFR Mutations from Plasma Under 3 Hours and Without Prior Cell-free DNA Extraction - Soo-Ryum Yang, USA



## Preliminary Program

All times CDT

- A 'Plasma-first' Molecular Profiling Approach Complements Actionable Mutation Detection in Suspected Lung Cancer Patients - Choudhury Yukti, Singapore

**== END ==**